Compare Lupin with FDC - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs FDC - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN FDC LUPIN/
FDC
 
P/E (TTM) x 40.7 22.1 184.4% View Chart
P/BV x 3.7 4.3 87.7% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 LUPIN   FDC
EQUITY SHARE DATA
    LUPIN
Mar-20
FDC
Mar-18
LUPIN/
FDC
5-Yr Chart
Click to enlarge
High Rs882319 276.6%   
Low Rs505164 307.9%   
Sales per share (Unadj.) Rs339.461.6 550.6%  
Earnings per share (Unadj.) Rs-5.99.9 -59.8%  
Cash flow per share (Unadj.) Rs15.512.0 129.3%  
Dividends per share (Unadj.) Rs6.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs276.773.2 378.2%  
Shares outstanding (eoy) m453.00174.40 259.7%   
Bonus/Rights/Conversions ESOPBB-  
Price / Sales ratio x2.03.9 52.2%   
Avg P/E ratio x-116.624.3 -480.5%  
P/CF ratio (eoy) x44.820.2 222.1%  
Price / Book Value ratio x2.53.3 75.9%  
Dividend payout %-100.90-   
Avg Mkt Cap Rs m314,20142,118 746.0%   
No. of employees `00018.35.5 330.9%   
Total wages/salary Rs m29,8682,167 1,378.5%   
Avg. sales/employee Rs Th8,400.61,943.7 432.2%   
Avg. wages/employee Rs Th1,632.0391.7 416.6%   
Avg. net profit/employee Rs Th-147.2313.7 -46.9%   
INCOME DATA
Net Sales Rs m153,74810,751 1,430.1%  
Other income Rs m4,838510 949.3%   
Total revenues Rs m158,58511,260 1,408.4%   
Gross profit Rs m24,8492,267 1,096.2%  
Depreciation Rs m9,702351 2,761.0%   
Interest Rs m3,63014 25,927.1%   
Profit before tax Rs m16,3552,411 678.3%   
Minority Interest Rs m4-5 -81.3%   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,571671 1,723.9%   
Profit after tax Rs m-2,6941,735 -155.3%  
Gross profit margin %16.221.1 76.6%  
Effective tax rate %70.827.8 254.2%   
Net profit margin %-1.816.1 -10.9%  
BALANCE SHEET DATA
Current assets Rs m154,1327,213 2,137.0%   
Current liabilities Rs m92,2522,104 4,385.2%   
Net working cap to sales %40.247.5 84.7%  
Current ratio x1.73.4 48.7%  
Inventory Days Days8254 150.6%  
Debtors Days Days12928 466.3%  
Net fixed assets Rs m89,0826,865 1,297.7%   
Share capital Rs m906175 517.1%   
"Free" reserves Rs m124,46112,586 988.9%   
Net worth Rs m125,36712,761 982.4%   
Long term debt Rs m17,9336 298,880.0%   
Total assets Rs m249,83915,041 1,661.0%  
Interest coverage x5.5173.2 3.2%   
Debt to equity ratio x0.10 30,423.0%  
Sales to assets ratio x0.60.7 86.1%   
Return on assets %0.411.6 3.2%  
Return on equity %-2.113.6 -15.8%  
Return on capital %8.719.0 46.0%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,4501,889 2,723.9%   
Fx outflow Rs m19,4700-   
Net fx Rs m31,9801,889 1,693.1%   
CASH FLOW
From Operations Rs m14,6881,498 980.3%  
From Investments Rs m11,070201 5,504.7%  
From Financial Activity Rs m-8,906-1,694 525.6%  
Net Cashflow Rs m16,85310 163,616.5%  

Share Holding

Indian Promoters % 46.6 68.9 67.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.7 240.4%  
FIIs % 31.9 7.5 425.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 19.0 53.2%  
Shareholders   98,259 23,730 414.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   BIOCON   WOCKHARDT  AUROBINDO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  

Compare LUPIN With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

FDC LTD. Announces Quarterly Results (3QFY20); Net Profit Up 67.7% (Quarterly Result Update)

Feb 10, 2020 | Updated on Feb 10, 2020

For the quarter ended December 2019, FDC LTD. has posted a net profit of Rs 733 m (up 67.7% YoY). Sales on the other hand came in at Rs 3 bn (up 26.0% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Apr 13, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS